Modeling Human Leukemia Using Immune-Compromised Mice

  • Fumihiko Ishikawa
  • Yariko Saito
  • Leonard D. Shultz


Various mutations have been found to cause leukemia, myeloid proliferative disorders, or lymphoid proliferative disorders in mice when directly introduced as transgenes or by transplantation of mouse hematopoietic cells expressing these genes through targeted vectors. These mouse models of hematological malignancies have provided important insights into leukemogenesis. However, models that facilitate studies of human leukemia cells in vivo are required to understand the biology of human leukemia. Studies of human leukemia cells that engraft in immunodeficient mouse models permit analyses of the mechanisms underlying human leukemic cell proliferation within the bone marrow, migration from the bone marrow into peripheral circulation, identification of specific microenvironmental niches for human leukemic cells, and the functional interactions of human leukemic cells with the elements of such niches. Such in vivo human leukemia models can also be used to simulate therapy...


Multiple Myeloma Acute Lymphocytic Leukemia Chronic Myeloid Leukemia Acute Myelogenous Leukemia Acute Myelogenous Leukemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bosma, G.C., Custer, R.P. & Bosma, M.J. A severe combined immunodeficiency mutation in the mouse. Nature 301, 527–530 (1983).PubMedCrossRefGoogle Scholar
  2. 2.
    Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869–877 (1992).PubMedCrossRefGoogle Scholar
  3. 3.
    Shinkai, Y. et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855–867 (1992).PubMedCrossRefGoogle Scholar
  4. 4.
    Shultz, L.D. et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154, 180–191 (1995).PubMedGoogle Scholar
  5. 5.
    Shultz, L.D. et al. NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J Immunol 164, 2496–2507 (2000).PubMedGoogle Scholar
  6. 6.
    Shultz, L.D. et al. NOD/LtSz-Rag1nullPfpnull mice: a new model system with increased levels of human peripheral leukocyte and hematopoietic stem-cell engraftment. Transplantation 76, 1036–1042 (2003).PubMedCrossRefGoogle Scholar
  7. 7.
    Christianson, S.W. et al. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J Immunol 158, 3578–3586 (1997).PubMedGoogle Scholar
  8. 8.
    Cao, X. et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2, 223–238 (1995).PubMedCrossRefGoogle Scholar
  9. 9.
    Sugamura, K. et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 14, 179–205 (1996).PubMedCrossRefGoogle Scholar
  10. 10.
    Ito, M. et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175–3182 (2002).PubMedCrossRefGoogle Scholar
  11. 11.
    Shultz, L.D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174, 6477–6489 (2005).PubMedGoogle Scholar
  12. 12.
    Ishikawa, F. et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106, 1565–1573 (2005).PubMedCrossRefGoogle Scholar
  13. 13.
    Honma, Y., Ishii, Y., Sassa, T. & Asahi, K. Treatment of human promyelocytic leukemia in the SCID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells. Leuk Res 27, 1019–1025 (2003).PubMedCrossRefGoogle Scholar
  14. 14.
    Kiser, M. et al. Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. Leukemia 15, 814–818 (2001).PubMedCrossRefGoogle Scholar
  15. 15.
    Pirruccello, S.J. et al. OMA-AML-1: a leukemic myeloid cell line with CD34+ progenitor and CD15+ spontaneously differentiating cell compartments. Blood 80, 1026–1032 (1992).PubMedGoogle Scholar
  16. 16.
    Terpstra, W. et al. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice. Leukemia 9, 1573–1577 (1995).PubMedGoogle Scholar
  17. 17.
    Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).PubMedCrossRefGoogle Scholar
  18. 18.
    Ailles, L.E., Gerhard, B., Kawagoe, H. & Hogge, D.E. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 94, 1761–1772 (1999).PubMedGoogle Scholar
  19. 19.
    Pearce, D.J. et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107, 1166–1173 (2006).PubMedCrossRefGoogle Scholar
  20. 20.
    Lumkul, R. et al. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia 16, 1818–1826 (2002).PubMedCrossRefGoogle Scholar
  21. 21.
    Yalcintepe, L., Frankel, A.E. & Hogge, D.E. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 108, 3530–3537 (2006).PubMedCrossRefGoogle Scholar
  22. 22.
    Feuring-Buske, M. et al. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17, 760–763 (2003).PubMedCrossRefGoogle Scholar
  23. 23.
    Ishikawa, fF. et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone marrow endosteal region. Nature Biotechnology 25, 1315–1321 (2007).PubMedCrossRefGoogle Scholar
  24. 24.
    Ninomiya, M. et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 21, 136–142 (2007).PubMedCrossRefGoogle Scholar
  25. 25.
    Liem, N.L. et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103, 3905–3914 (2004).PubMedCrossRefGoogle Scholar
  26. 26.
    Nijmeijer, B.A. et al. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Experimental Hematology 29, 322–329 (2001).PubMedCrossRefGoogle Scholar
  27. 27.
    Schimmel, K.J., Nijmeijer, B.A., van Schie, M.L., Falkenburg, J.H. & Guchelaar, H.J. Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia. Leuk Res (2007).Google Scholar
  28. 28.
    Nijmeijer, B.A., van Schie, M.L., Verzaal, P., Willemze, R. & Falkenburg, J.H. Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia. Exp Hematol 33, 1172–1181 (2005).PubMedCrossRefGoogle Scholar
  29. 29.
    Nijmeijer, B.A., Willemze, R. & Falkenburg, J.H. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. Blood 100, 654–660 (2002).PubMedCrossRefGoogle Scholar
  30. 30.
    Jamieson, C.H. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351, 657–667 (2004).PubMedCrossRefGoogle Scholar
  31. 31.
    Jaiswal, S. et al. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci U S A 100, 10002–10007 (2003).PubMedCrossRefGoogle Scholar
  32. 32.
    Hoyle, C.F. & Negrin, R.S. Engraftment of chronic myeloid leukemia in SCID mice. Hematol Oncol 16, 87–100 (1998).PubMedCrossRefGoogle Scholar
  33. 33.
    Namikawa, R., Ueda, R. & Kyoizumi, S. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 82, 2526–2536 (1993).PubMedGoogle Scholar
  34. 34.
    Sawyers, C.L., Gishizky, M.L., Quan, S., Golde, D.W. & Witte, O.N. Propagation of human blastic myeloid leukemias in the SCID mouse. Blood 79, 2089–2098 (1992).PubMedGoogle Scholar
  35. 35.
    Sirard, C. et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 87, 1539–1548 (1996).PubMedGoogle Scholar
  36. 36.
    Beran, M. et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 53, 3603–3610 (1993).PubMedGoogle Scholar
  37. 37.
    Skorski, T., Nieborowska-Skorska, M. & Calabretta, B. A model of Ph' positive chronic myeloid leukemia-blast crisis cell line growth in immunodeficient SCID mice. Folia Histochem Cytobiol 30, 91–96 (1992).PubMedGoogle Scholar
  38. 38.
    Dazzi, F. et al. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood 92, 1390–1396 (1998).PubMedGoogle Scholar
  39. 39.
    Lewis, I.D., McDiarmid, L.A., Samels, L.M., To, L.B. & Hughes, T.P. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood 91, 630–640 (1998).PubMedGoogle Scholar
  40. 40.
    Verstegen, M.M., Cornelissen, J.J., Terpstra, W., Wagemaker, G. & Wognum, A.W. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice. Leukemia 13, 618–628 (1999).PubMedCrossRefGoogle Scholar
  41. 41.
    Wang, J.C. et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 91, 2406–2414 (1998).PubMedGoogle Scholar
  42. 42.
    Eisterer, W. et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19, 435–441 (2005).PubMedCrossRefGoogle Scholar
  43. 43.
    Carlo-Stella, C. et al. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Exp Hematol 34, 721–727 (2006).PubMedCrossRefGoogle Scholar
  44. 44.
    Ito, K. et al. 1′-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res 65, 4417–4424 (2005).PubMedCrossRefGoogle Scholar
  45. 45.
    Mitsiades, C.S. et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 63, 6689–6696 (2003).PubMedGoogle Scholar
  46. 46.
    Tassone, P. et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106, 713–716 (2005).PubMedCrossRefGoogle Scholar
  47. 47.
    Yaccoby, S., Barlogie, B. & Epstein, J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92, 2908–2913 (1998).PubMedGoogle Scholar
  48. 48.
    Dewan, M.Z. et al. Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice. Cancer Sci 95, 564–568 (2004).PubMedCrossRefGoogle Scholar
  49. 49.
    Bonnet, D. & Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730–737 (1997).PubMedCrossRefGoogle Scholar
  50. 50.
    Feuring-Buske, M. & Hogge, D.E. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(–) progenitor cells from patients with acute myeloid leukemia. Blood 97, 3882–3889 (2001).PubMedCrossRefGoogle Scholar
  51. 51.
    Sperr, W.R. et al. Human leukaemic stem cells: a novel target of therapy. European journal of clinical investigation 34 Suppl 2, 31–40 (2004).PubMedCrossRefGoogle Scholar
  52. 52.
    Buccisano, F. et al. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol 125, 203–212 (2004).PubMedCrossRefGoogle Scholar
  53. 53.
    Jordan, C.T. et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777–1784 (2000).PubMedCrossRefGoogle Scholar
  54. 54.
    Hosen, N. et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A 104, 11008–11013 (2007).PubMedCrossRefGoogle Scholar
  55. 55.
    Guzman, M.L. et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163–4169 (2005).PubMedCrossRefGoogle Scholar
  56. 56.
    Guzman, M.L. et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 99, 16220–16225 (2002).PubMedCrossRefGoogle Scholar
  57. 57.
    Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F. & Dick, J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12, 1167–1174 (2006).PubMedCrossRefGoogle Scholar
  58. 58.
    Krause, D.S., Lazarides, K., von Andrian, U.H. & Van Etten, R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 12, 1175–1180 (2006).PubMedCrossRefGoogle Scholar
  59. 59.
    Dar, A., Kollet, O. & Lapidot, T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol 34, 967–975 (2006).PubMedCrossRefGoogle Scholar
  60. 60.
    Tavor, S. et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64, 2817–2824 (2004).PubMedCrossRefGoogle Scholar
  61. 61.
    Hotfilder, M. et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res 65, 1442–1449 (2005).PubMedCrossRefGoogle Scholar
  62. 62.
    Castor, A. et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 11, 630–637 (2005).PubMedCrossRefGoogle Scholar
  63. 63.
    George, A.A. et al. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood 97, 3925–3930 (2001).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Fumihiko Ishikawa
    • 1
  • Yariko Saito
  • Leonard D. Shultz
  1. 1.Research Unit for Human Disease ModelsRIKEN Research Center for Allergy and ImmunologyJapan

Personalised recommendations